Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - February 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 14 Million Units priced at $0.24 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per Common Share for a period of...
2023-02-01 8:31 PM EST
The Force Family Office Engaged by Hemostemix
Calgary, Alberta--(Newsfile Corp. - January 31, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is plugged into the largest network of family offices in the United States via its agreement with the Force Family Office. In 2022, The Force Family Office hosted more than 150 events, connecting family offices with private and public companies for co-investment. Founded in 2020 by Steven Saltzstein with a singular focus to...
2023-01-31 9:26 AM EST
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
Calgary, Alberta--(Newsfile Corp. - January 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its Trademark, Your Fountain of Youth, was granted protection in Switzerland by its Trademark Office. Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., has received a Statement of Grant of Protection from the Swiss Trademark Office, and notice of the grant from the World Intellectual Property Organization....
2023-01-30 3:50 PM EST
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your Fountain of Youth explains the benefit of leveraging your synergetic cell population as ACP-01 and it explains Hemostemix' business model," stated Thomas...
2023-01-26 3:27 PM EST
Hemostemix Wins Arbitration Decision
Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that it was entered into in violation of Dr. Burchardt's duties as a director under sections 120 and 122 of the Business Corporations Act (Alberta), and determined that he...
2023-01-24 9:00 AM EST
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is hiring four new biotechnologists to re-establish the Company's production of ACP-01 in Montreal. The Company is hiring an experienced autologous stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists. Coincidentally, Hemostemix has applied for Federal and Provincial grant...
2023-01-23 9:37 AM EST
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind...
2023-01-19 11:28 AM EST
Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
Calgary, Alberta--(Newsfile Corp. - December 8, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus, issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. The Trademark is registered initially for 10 years. The Company's has a right to renew for additional 10-year periods by...
2022-12-08 2:34 PM EST
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") thanks Mr. Neim Malo, founder of Beefstro's, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s). Cannot view this video? Visit: https://www.youtube.com/watch?v=1ezFC0oIU9s Mr. Neim Malo is an award-winning restauranteur, and founder
2022-11-30 10:02 AM EST
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube. Cannot view this video? Visit: https://www.youtube.com/watch?v=KTuq3Oy7WU0 Mr. Howard "Howie" Lindeman
2022-11-17 8:29 AM EST
Hemostemix Announces Advancements in Its Automation of Production
Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating our manual methods of angiogenic cell precursor (ACP-01) production. ACTS will...
2022-11-15 8:43 AM EST
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductions and due diligence responses; help position ACP-01 as a candidate to be the first-to-patient autologous stem cell treatment of heart disease;...
2022-10-26 10:39 AM EDT
Hemostemix Announces Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference on Wednesday, October 26th at 12:00 EDT. Attendees may use the following link to attend: (https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=hmtxf). ABOUT HEMOSTEMIX...
2022-10-25 11:36 AM EDT
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
Calgary, Alberta--(Newsfile Corp. - October 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.'s study of NCP-01. The spinal cord injury repair study will focus on the improvement of motor function and the decrease of pain following the injection of NCP-01 into the spinal fluid pathway of small animals. The global neuropathic pain market was...
2022-10-19 9:43 AM EDT
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on...
2022-10-04 9:00 AM EDT
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board. Dr. von Schwarz is a US based world renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine at UCLA and UC Riverside. He joined Cedars Sinai Medical Center and UCLA as Director of...
2022-09-27 9:00 AM EDT
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board. Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and Health Sciences at McGill University, the Director of the McGill Regenerative Medicine Network, and a Professor in the Department of Pharmacology and...
2022-09-20 8:45 AM EDT
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board. Dr. Giannetti received her Medical Degree from McGill University. After training in cardiology at McGill, she went on to pursue a Fellowship in Heart Failure and Cardiac Transplantation at Stanford University in California. She returned to McGill to...
2022-09-16 10:32 AM EDT
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board. Since 2019, Dr. Johannes Grillari is the director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma) - the Research Center in cooperation with AUVA, Vienna, Austria which is the central research unit of seven trauma centers and four rehabilitation...
2022-09-15 11:14 AM EDT
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board. Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Transplantation Program, and Director of the Mechanical Circulatory Support Program. He is also Associate Member of the McGill University Department...
2022-09-14 1:02 PM EDT